Vascular Effects of Hesperidin in Metabolic Syndrome
Phase 2
- Conditions
- Endothelial DysfunctionMetabolic Syndrome
- Interventions
- Drug: Placebo
- Registration Number
- NCT00914251
- Lead Sponsor
- University of Rome Tor Vergata
- Brief Summary
It has been suggested that cardiovascular risk factors either independently or in cluster (metabolic syndrome) increase the risk of both type 2 diabetes (DM2) and cardiovascular diseases (CVD). Consumption of citrus fruits is linked to reduced cardiovascular morbidity and mortality. Hesperidin is a flavanone abundant in citrus fruit with putative vasodilator actions in vitro. While molecular mechanisms of vascular actions of hesperidin begin to be explored, no data on in vivo vascular effect of this flavanone has been ever acquired.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Metabolic Syndrome (ATPIII criteria)
- BMI <35
- Age 20-55
Exclusion Criteria
- History of cancer.
- History of cardiovascular diseases.
- Any other acute or chronic illness which requires administration of steroids or other drugs able to interfere with glucose or lipid metabolism.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo Placebo - Hesperidin, 500 mg per day Hesperidin 500 mg daily of oral Hesperidin for 3 weeks
- Primary Outcome Measures
Name Time Method Safety of oral supplementation of hesperidin 3 weeks
- Secondary Outcome Measures
Name Time Method Endothelial function assessed by FMD %. Inflammatory status assessed by biochemical markers. 3 weeks
Trial Locations
- Locations (1)
University of Rome Tor Vergata
🇮🇹Rome, Italy